NGS TESTING FOR
RARE CANCERS
Rare cancer patients are no longer excluded from targeted treatment development by population size. Tumour-agnostic approvals and molecular-matched basket trials include them by molecular logic -- if the alteration is present, the treatment is accessible.
How Precision Oncology Expands Access for Rare Cancers
Rare cancers often share molecular features with common cancers. The shared molecular target is the access point -- regardless of the tissue of origin.
Tumour-Agnostic Approvals
MSI-H/pembrolizumab (2017). NTRK fusions/larotrectinib and entrectinib (2018-2019). TMB-high/pembrolizumab (2020). RET fusions/selpercatinib (2022). A thymic carcinoma with MSI-H qualifies. A primary peritoneal cancer with an NTRK fusion qualifies. Cancer type does not determine access.
FGFR and IDH Alterations
FGFR2 fusions in cholangiocarcinoma and basket trials for other FGFR-altered cancers. IDH1/IDH2 mutations established in glioma and AML, also found in cholangiocarcinoma and chondrosarcoma -- basket trials extend to other IDH-mutated cancers.
Sarcoma-Specific and Molecular Programmes
EWSR1 fusions in Ewing sarcoma, SS18-SSX in synovial sarcoma, MDM2 amplification in liposarcoma. Comprehensive NGS identifies these and connects patients to sarcoma-specific programmes as well as broader molecular-matched options.
Frequently Asked Questions
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Questions About NGS Testing and Treatment Access for Your Rare Cancer?
CancerFax specialises in connecting rare cancer patients with tumour-agnostic treatment options and molecular-matched basket trials worldwide.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.